Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to be able to supply an experimental combination of drugs called
3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may
benefit from treatment.